Evidence map›Paper›PMID 42023818›Full record

ArticleCancer science2026

Decreased Expression of FAT4 Promotes Multiple Myeloma Proliferation and Migration by Targeting the Hippo/YAP Pathway.

Lina Zhang, Na Shen, Xin Cheng, Qinglin Shi, Lijuan Chen, Xuxing Shen

Abstract read
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lina ZhangDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.ORCID https://orcid.org/0000-0002-3176-4922
Na ShenDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
Xin ChengDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
Qinglin ShiDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
Lijuan ChenDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.ORCID https://orcid.org/0000-0002-6497-1194
Xuxing ShenDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.ORCID https://orcid.org/0000-0003-0110-1463

Funding

China Postdoctoral Science Foundation 2024M751467Nanjing Medical University Science and Technology Development Fund NMUB20230161National Natural Science Foundation of China 82070223National Natural Science Foundation of China 82200223National Natural Science Foundation of China 82500276Natural Science Foundation of Jiangsu Province BK20240255Social Development Project of Jiangsu Science and Technology Plan BE2022810
6 · The paper itself

Abstract

FAT4 is a member of the protocadherin family and plays an important role in various types of tumors. Multiple myeloma (MM) is a common hematological malignancy. Whole-exome sequencing revealed that FAT4 is a frequently mutated driver gene of MM, but its biological function in MM remains elusive. We performed targeted gene sequencing on MM cells isolated from 161 patients and retrospectively analyzed the clinical data of these patients. The mutation frequency of FAT4 in newly diagnosed MM patients was 15.5%, ranking as the sixth most frequently mutated gene. FAT4 mutations were associated with poor prognosis of MM and decreased expression of FAT4. In vitro experiments demonstrated that FAT4 knockdown promoted the proliferation and migration in MM cells. We then confirmed these findings in vivo using zebrafish and mouse models. We further revealed that FAT4 exerted tumor suppressor effects by targeting the Hippo/YAP pathway in MM. Knockdown of FAT4 promoted the nuclear translocation of YAP. Interestingly, FAT4 did not regulate YAP nuclear entry through the canonical phosphorylation cascade. Instead, coimmunoprecipitation assays revealed the interaction between FAT4 and YAP. This interaction retained YAP in the cytoplasm, thereby blocking its nuclear translocation. Our findings highlight the tumor-suppressive role of FAT4 in MM and uncover a novel mechanism by which FAT4 regulates the Hippo/YAP pathway.

Indexed as

Adaptor Proteins, Signal TransducingCadherinsMultiple MyelomaProtein Serine-Threonine KinasesTranscription FactorsAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHippo Signaling PathwayHumansMaleMiceMutationAdaptor Proteins, Signal TransducingCadherinsFAT4 protein, humanProtein Serine-Threonine KinasesTranscription FactorsTumor Suppressor ProteinsYAP1 protein, humanYAP-Signaling ProteinsFAT4multiple myelomanext generation sequencingYAPzebrafish

Identifiers

PMID42023818
PMCPMC13327098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.